今すぐ寄付してください会員になる

カート (0)

DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか？ or パスワードをお忘れですか？

Not a Member?

アカウントを作成して参加。

Bethesda North Marriott Hotel and Conference Center

2018年10月02日 (火) 午前 7:00 - 2018年10月03日 (水) 午後 3:00

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

Measuring Impact in Patient-Centered Drug Development Conference

戻る Agenda

Session 4: Where and When Should We be Measuring?

Session Chair(s)

Cynthia Grossman, PhD

Cynthia Grossman, PhD

Director, Science of Patient Input

FasterCures, A Center of the Milken Institute, United States

Looking across the R&D lifecyle, there are several opportunities to measure the degree of patient-centric practices and possible impacts. Beyond identifying opportunities, we have yet to discuss issues such as how the point in the lifecycle might drive the types of patient-centered practices and how some activities may require different measurement approaches. This session will dive into opportunities to better match timing of measurement to demonstrate the impact of patient engagement across the full lifecycle.

Learning Objective : At the conclusion of this session, participants should be able to:
Identify the specific time points along the product lifecycle where patient engagement could be measured
Define at least three issues to consider related to the timing measurement of PE appropriately
Give one example of how the measurement of PE would differ depending on timing of the product lifecycle

Speaker(s)

Mathieu Boudes, PhD

Where and When Should We be Measuring?

Mathieu Boudes, PhD

Montsouris Consilium, France

Patient Engagement Director

Bray Patrick-Lake, MS

Measuring the Value & Impact of Patient Engagement in Clinical Trials

Bray Patrick-Lake, MS

FDA, United States

Senior Digital Health Specialist, DDH, CDRH

James Valentine, JD, MHS

Measuring Impact in Patient Engagement: Regulatory Opportunities

James Valentine, JD, MHS

Hyman, Phelps & McNamara, PC, United States

Director